title: 125I brachytherapy alone for recurrent or locally advanced adenoid cystic carcinoma of the oral and maxillofacial region.
abstract: OBJECTIVE
  This retrospective study was to evaluate the local control and survival of (125)I brachytherapy for recurrent and/or locally advanced adenoid cystic carcinoma (ACC) of the oral and maxillofacial region.
  
  
  METHODS
  A total of 38 patients with recurrent and/or locally advanced ACC of the oral and maxillofacial region received (125)I brachytherapy alone from 2001-2010. Twenty-nine were recurrent cases following previous surgery and radiation therapy. The other 9 cases involved primary tumors. Overall, 12 tumors were located in the major salivary glands, 12 in the minor salivary glands, and 14 in the paranasal region, the nasal cavity or the skull base. The prescribed dose was 100-160 Gy.
  
  
  RESULTS
  Patients were followed for 12-122 months (median 51 months). The 2-, 5-, and 10-year local tumor control rates were 86.3, 59, and 31.5 %, respectively. The 2-, 5-, and 10-year overall survival rates were 92.1, 65 and 34.1 %, respectively. Tumors > 6 cm had significantly lower local control and survival rates. No severe complications were observed during follow-up.
  
  
  CONCLUSIONS
  (125)I brachytherapy is a feasible and effective modality for the treatment of locally advanced unresectable or recurrent ACC.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, P. R. China.
authors.forename: M-W
authors.initials: MW
authors.lastname: Huang
authors.forename: L
authors.initials: L
authors.lastname: Zheng
authors.forename: S-M
authors.initials: SM
authors.lastname: Liu
authors.forename: Y
authors.initials: Y
authors.lastname: Shi
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.forename: G-Y
authors.initials: GY
authors.lastname: Yu
authors.forename: J-G
authors.initials: JG
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000379:methods*; D003528:Carcinoma, Adenoid Cystic / Q000473:pathology / Q000532:radiotherapy*; D002648:Child; D018450:Disease Progression; D005153:Facial Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000532:radiotherapy; D009669:Nose Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D012468:Salivary Gland Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D019292:Skull Base Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D055815:Young Adult
chemical_list: D007457:Iodine Radioisotopes